Chronic obstructive pulmonary disease patients newly prescribed non-benzodiazepine benzodiazepine receptor agonists (NBZRAs) such as zolpidem (Ambien, Intermezzo and other brands), a class of hypnotic drugs prescribed for insomnia, did not have an increased risk of exacerbations requiring hospitalizations or of death than those prescribed other types of hypnotics, according to research published at the ATS 2023 International Conference.
Hypnotic drug class may not have increased the risk of exacerbations and death among COPD patients
- Thread starter Educator
- Start date